Table 3. Median number of AETDs of antimalarials sold during the week preceding the survey.
| COUNTRY2 | ||||||||
| ANTIMALARIAL TYPE | BENIN | CAMBODIA | DRC | NIGERIA | UGANDA | ZAMBIA | ||
| Formulation1 | N = 201 | N = 93 | N = 137 | N = 136 | N = 127 | N = 40 | ||
| ACT | All | Median | 0.0 | 2.0 | 68.5 | 137.9 | 22.0 | 35.7 |
| IQR | 0.0–45.0 | 0.0–10.0 | 7.5–327.5 | 12.8–794.0 | 4.8–94.4 | 0.8–176.8 | ||
| Tablet | Median | 0.0 | 2.0 | 59.7 | 120.0 | 21.9 | 31.0 | |
| IQR | 0.0–35.0 | 0.0–10.0 | 7.4–287.9 | 11.8–730.4 | 4.0–86.7 | 0.0–96.3 | ||
| Oral liquid | Median | 0.0 | 0.0 | 1.9 | 0.0 | 0.0 | 0.0 | |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–29.3 | 0.0–26.3 | 0.0–0.0 | 0.0–3.8 | ||
| AMT | All | Median | 0.0 | 0.0 | 8.3 | 42.0 | 15.0 | 0.0 |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–83.7 | 3.8–272.1 | 2.3–34.8 | 0.0–9.2 | ||
| Tablet | Median | 0.0 | 0.0 | 0.0 | 28.1 | 7.7 | 0.0 | |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–10.1 | 0.0–155.3 | 0.0–18.8 | 0.0–0.0 | ||
| Oral liquid | Median | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–4.3 | 0.0–17.3 | 0.0–0.0 | 0.0–0.0 | ||
| Injectable | Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–15.1 | 0.0–2.6 | 0.0–9.5 | 0.0–3.9 | ||
| nAT | All | Median | 222.1 | 0.0 | 327.8 | 562.9 | 304.9 | 320.9 |
| IQR | 21.3–1104.1 | 0.0–0.0 | 65.3–1519.0 | 163.6–2006.6 | 52.1–1523.7 | 13.3–1260.4 | ||
| Tablet | Median | 141.9 | 0.0 | 226.2 | 392.3 | 203.8 | 301.6 | |
| IQR | 9.5–809.5 | 0.0–0.0 | 24.5–1167.7 | 90.4–1649.2 | 10.3–1053.9 | 0.0–1200.0 | ||
| Oral liquid | Median | 0.0 | 0.0 | 6.6 | 26.8 | 28.8 | 0.0 | |
| IQR | 0.0–15.3 | 0.0–0.0 | 0.0–70.6 | 0.0–101.8 | 3.6–78.8 | 0.0–3.4 | ||
| Injectable | Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| IQR | 0.0–0.0 | 0.0–0.0 | 0.0–13.9 | 0.0–4.9 | 0.0–19.0 | 0.0–0.0 | ||
N: number of wholesalers included in the sales volume analysis; ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non-artemisinin therapy; IQR: inter-quartile range. 1 The values for median number of AETDs sold reported for ‘all’ formulations include all dosage forms (tablets, suppositories, oral liquids, injectables and granules); however because so few wholesalers stocked suppositories or granules, and so few of these product types were observed during the audit, these dosage forms have been excluded from the tables here. 2 Notes on imputation: The number of wholesalers included in N whose sales volumes were set to zero as they did not stock antimalarials at the time of the survey but did at some point during the 3 months preceding the survey was 2 in Benin, 5 in Cambodia, 2 in the DRC, 2 in Nigeria, 1 in Uganda and 0 in Zambia. The number of wholesalers identified during the study for whom sales volumes were excluded or set to missing because they did not meet inclusion criteria or for various other reasons (see Table 2) was 17 in Benin, 9 in Cambodia, 24 in the DRC, 68 in Nigeria, 14 in Uganda and 17 in Zambia. The percentage of audited antimalarial products that had missing sales volumes data which was imputed using the mi impute pmm command in Stata was 23.7% in Benin, 3.9% in Cambodia, 9.0% in the DRC, 35.7% in Nigeria, 3.4% in Uganda and 13.3% in Zambia.